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The major contribution of this study lies in the development of a methodology for studying patterns of dynamics of emerging
technologies. Our main research question includes: How can patterns of technology dynamics of emerging technologies be conceptualized?
And more specifically to the Dutch biotech case: Which patterns of technology dynamics could be discerned at Dutch dedicated life sciences
firms (DDLSFs)? We develop a new approach for conceptualizing patterns of technology dynamics, using an ‘opportunity matrix’ as the
starting point and presenting these patterns by network visualization. We illustrate this new conceptualization by an exemplary case
study of emerging biotechnology developments in the Dutch/life sciences sector. Our results show a growing diversity within subsequent
populations of newly founded firms over time. Individual newly founded firms were shown to be mainly specialists, working on one
technological subfield.
r 2008 Elsevier Ltd. All rights reserved.
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Emerging technologies in high-technology, knowledge-
based sectors, such as biotechnology and nanotechnology,
are characterized by rapid development in terms of
significance and development rate of new ideas and
technologies. A gradually broadening range of scientific
and technological fields is included, which keep changing as
science and technology progress over time. There are high
expectations, but also many uncertainties whether these
expectations will be realized (Hopkins et al., 2007).
According to Pisano (2006), the performance of the current
biotech business is disappointing as not many new drugs
have hit the market and the expected breakthrough in
research and development (R&D) productivity has yet to
materialise. Greater emphasis on intergration and
long-term learning rather than shorter-term IPR focus is
necessary (Pisano, 2006). Prior to any attempt to steer thee front matter r 2008 Elsevier Ltd. All rights reserved.
chnovation.2008.09.005
ing author. Tel.: +3130 2531625; fax: +31 30 2532746.
ess: tessa.vandervalk@tno.nl (T. van der Valk).future direction of emerging technological developments
using policy measures, developments that have occurred so
far need to be explicated. In this paper, we examine
technology dynamics generated by Dutch dedicated life
sciences firms (DDLSFs).
To gain insight into technology dynamics, patent data
have been a regular source of information (see for instance
(Duysters and Hagedoorn, 1998; Malerba and Orsenigo,
1999; Breschi et al., 2003; Saviotti et al., 2005; Zhang et al.,
2007; Quintana-Garcia and Benavides-Velasco, 2008).
One of the advantages of the use of patents in studying
technological developments over time is that they can be
easily analysed as a temporal sequence using either the date
of application, publication or granting. However, in
emerging technological fields the applicability of patent
data for the analysis of technology dynamics is question-
able. First of all, the firms active in such a field and
therefore contributing to technological developments are
generally young and small firms. Many of these firms do
not have patents yet, to some extent due to high costs and
difficulties in protecting the patent when infringement
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ogy firms are spin-offs from research institutes applying
knowledge that has already been patented by these research
institutes, and these patents cannot always be traced back
to the firm. This particular situation is not unique for the
Dutch life sciences population, but may apply to all
technological fields in which start-ups are considered to
contribute significantly to technological change. Instead of
applying patent analysis, we have therefore conducted the
analysis of technology dynamics by focussing on technol-
ogies in use, as was also done by Lemarié et al. (2000). As
the usefulness of patent data is limited, focussing on
technologies in use can be expected to provide a more
elaborate overview of the actual technological develop-
ments. In order to analyse the dynamics of technologies in
use by start-ups founded from 2000 to 2004, we use the
year of founding of these firms. Due to their relatively
limited age these firms are not likely to have completely
changed their technology portfolio since founding. This
will be further elaborated on in Section 3.
In emerging technological fields, demand is unclear or
not articulated yet, reducing the applicability of diffusion
research. A fruitful approach that has been applied to
emerging technologies is the socio-cognitive and institu-
tional approach (Bijker and Law, 1992; Garud and Rappa,
1994; Van de Ven et al., 1999; Rao and Singh, 2001). These
studies have provided in-depth analyses of ways in which a
specific invention can evolve in laboratories and new
business ventures, and very often they report shifting
evaluation criteria as to the function and quality of
inventions, even in short time periods. These studies show
how volatile further development of an invention is. As
opposed to the cases of specific inventions addressed in
these studies, this study aims to address technology
development at a much more general level. By focussing
on biotechnology-related developments driven by the
population of DDLSFs we are able to unravel patterns
of technology dynamics of an emerging technological field,
as well as show how the founding of new firms has
generated these patterns. Overall, this implies a broader
perspective on technology dynamics, complementing the
in-depth studies of individual inventions referred to above.
Building on earlier work on technological regimes we will
advance a set of concepts and measures that enable a
systematic analysis of patterns of technology dynamics in
emerging technological fields. From the technological
regime literature (Nelson and Winter, 1982; Malerba and
Orsenigo, 1996; Breschi et al., 2003) we derive the notion of
technological opportunities, and from the population
ecology literature the notion of the founding of firms over
time. As opposed to most of these studies our key
indicators are not patents, but technologies in use, and
not sectors, but foundings of firms within a sector.
The central research question of this paper then becomes:
How can patterns of technology dynamics of emerging
technologies be conceptualized in general? And morespecifically with respect to the case of Dutch dedicated
life sciences firms: Which patterns of technology dynamics
could be discerned at Dutch dedicated life sciences firms?
In answering this latter research question, we focus on
DDLSFs that have been founded in the period
2000–2004. These central research questions issue
several more specific research questions examined in
this paper:
(1) Which technological fields can be discerned in modern
biotechnology, and how can these be classified?
(2) Which patterns in the development of the technological
diversity of the population of newly founded firms could
be discerned for subsequent annual populations of these
newly founded firms?
(3) To what extent are Dutch dedicated life sciences firms,
newly founded in the period 2000–2004 specialists,
focussing on one specific technological (sub)field, and
to what extent do they combine various technological
fields?Recently, several studies have focussed on organizational
aspects and their dynamics with regard to high-technology
firms, especially where firms working in biotechnology
are concerned (Bigliardi et al., 2005; Nosella et al., 2005;
Terziovski and Morgan, 2006; Hall and Bagchi-Sen, 2007;
Willemstein et al., 2007; Aharonson et al., 2008). In
such studies, the technologies focussed on by these firms
are left implicit, and attention is primarily given to
organizational aspects of innovation processes. For
example, in the process model of ‘Biotech innovation
management’ as presented by Khilji et al. (2006), ‘science
and technology’ is proposed to be the starting point of
the innovation process, whereas little attention is paid
to the contents of this ‘science and technology’. However,
as Kash and Rycroft (2002, p. 582) state, ‘‘it is the
simultaneous evolution of technology and organizat-
ions that creates novelty and variety in technological
products, processes and in the networks themselves.’’
This paper aims to complement such studies focussing
on organizational dynamics by unravelling technology
dynamics.
In order to take the diversity of technological subfields
within biotechnology into account, we do not focus on a
single, specific population of firms, e.g. tissue engineering
firms only, but we study whether individual technological
subfields become more prominent compared to others over
time. If this is the case, there could be a collective direction
in which this technological field develops. If not, firms are
mostly niche players.
Furthermore, this paper addresses technological combi-
nations made by individual firms across the opportunity
set. This is important because other researches have shown
how dominant the initial technologies of firms are in deter-
mining future developments. Lemarié et al. (2000, p. 9)
show that the technologies in use by a sample of UK,
German and French biotechnology firms could be traced to
their year of founding. The internal renewal of technologies
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the founding of new firms is. For this reason it is interesting
to study whether, and if so, how many, firms already
combine technologies at founding. One might argue that
the more combinations of technologies are made by firms
across a set of technological opportunities, the larger the
innovation opportunities in that population. As indicated
by McKelvey et al. (2004), the development of new
knowledge and technologies involves ongoing, complex,
dynamic processes within society and these affect, in turn,
the development of innovation opportunities. Focussing on
the technological opportunities and patterns of technology
dynamics in biotechnology firms might shed light on ways
to better organize vertical integration, complement cross-
disciplinary research projects, and share inventions with
research institutes, which, according to Pisano (2006), are
strategies to overcome the current difficulties in the biotech
sector. The policy relevance of this study derives from
policy debates in the EU concerning emerging technologies
such as biotechnology. These developments started much
earlier in the UK, France and Germany than in the
Netherlands. Only in the late 1990s, biotechnology was
identified by the Dutch government as an important
enabling technology for the development of a national
knowledge-based economy, which is regarded as a pre-
requisite for sustaining societal wealth and welfare in the
Netherlands in the near future. An analysis of the Ministry
of Economic Affairs carried out in 1998 showed that the
Dutch biopharmaceutical sector was lagging behind sectors
of neighbouring countries, the main barriers being that
Dutch knowledge institutes lacked a business culture
(Ministry of Economic Affairs, 1999). The results of
scientific research were seldom commercialized. There
was not enough venture capital available for start-ups
and there was a shortage of facilities, such as office and
laboratory space (Ministry of Economic Affairs, 1999).
From the year 2000 onwards, possibly stimulated by
government initiatives that started in these years such as
the BioPartner Network programme, opportunities deriv-
ing from developments in modern biotechnology have led
to the founding of 109 new firms focussing on products and
processes based on these developments, and related
supporting technologies (BioPartner, 2005). These firms
are referred to as dedicated life sciences start-ups. In this
research, we study the technologies used by these firms and
relate these to common technological fields in biotechnol-
ogy.
Nowadays, the Dutch life sciences sector is still in an
early stage of development and consists of about 160
primarily small, privately held, often loss-making, entre-
preneurial firms. Compared to other European populations
of life sciences firms the Dutch firms are particularly
young. Overall, the number of firms is similar to the
numbers active in countries of comparable size, such as
Denmark and Belgium (Critical I, 2006). These start-ups
mostly began as spin-offs from Dutch academic research
groups trying to commercialize new research findings in thebiotechnological field. It is expected that the surviving
start-up firms will be able to contribute to the development
of a new high-technology, knowledge-based industry with-
in the Netherlands.
To summarize, this paper aims to develop a new method
for unravelling technology dynamics, and applies this
method to the case of biotechnology developments in the
Netherlands. Section 2 will present some theoretical
notions on concepts of technology dynamics, at the
population level as well as the level of the firm. The
opportunity matrix will be introduced, leading to a
conceptualization of patterns of technology dynamics.
Section 3 will discuss the rapid development of modern
biotechnology, and gives a classification of the important
science and technological fields in biotechnology
developments in general. It will subsequently describe the
research methodology applied. Section 4 will present the
results. In Section 5, the findings will be discussed. Finally,
Section 6 will present the conclusions drawn from these
results, as an answer to the central research question stated
above.
2. Theoretical notions on patterns of technology dynamics:
towards a new conceptualization
In population ecology there is a line of work that
addresses firm foundings and technology cycles. The
research on technological regimes and r-to-K transitions
in population ecology comes closest to relating technology
development to firm foundings, as is pursued in this study.
In emerging technological fields, the population of
organizations dedicated to these fields is low at first.
The number of organizations increases over time, as
specialist firms identify and subsequently exploit ‘new
resource opportunities’ (Baum and Rao, 2004). These
specific resource opportunities can be perceived as niches,
in which specialist organizations attempt to exploit their
relatively narrow knowledge portfolios (Brittain and
Freeman, 1980). In biotechnology, these specialist organi-
zations are often founded by scientists (Fuchs and Krauss,
2003). As a population grows, the availability of resources
decreases, which reduces chances of survival of specialist
firms, and induces the appearance of generalist organiza-
tions capable of competing ‘‘yon the basis of efficiency
for the mass markety’’ (Baum and Rao, 2004, p. 228).
Therefore, emerging technological fields such as biotech-
nology may be expected to be characterized by an
increasing number of small, young, specialist organiza-
tions, who fill their own specific technological niche.
This population of organizations may then be considered
homogenous with regard to the breadth of the technology
portfolio of the individual organizations, which is low
as their portfolios are specialized, but heterogeneous
with regard to the specific content of these portfolios.
Such a specialization of firms in biotechnology was also
indicated by Pyka and Saviotti (2001), who stress the role
of such firms as either translators of new knowledge or
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refer to these new organizations as ‘specialized technology
originators.’
Over time, strategies with regard to technology devel-
opment of successful firms might be imitated (Brittain and
Freeman, 1980), but the increasing competition for
resources within a specific niche might also induce
variation within the growing population over time. When
an emerging technology is concerned such issues are yet to
be resolved.
To develop an in-depth conceptualization of variation,
and to link technology dynamics and founding we adopt
one of the elements advanced by Malerba and Orsenigo
(1996), namely the opportunity conditions. They relate
technological opportunities to the potential of innovation
within a specific field (Malerba and Orsenigo, 1996, p. 453).
These technological opportunities are not stable over time;
on the contrary, their extent and focus change over time, as
new technological (sub) fields emerge and others become
more established. Moreover, the rate of technological
progress ‘‘depends on the technological ‘‘distance’’ from
limits, both prior and subsequent’’ (Ayres, 1994, p. 67).
Thus, the technological opportunities depend, partly, on
non-economic factors and constraints, such as the physical
properties of materials, but also on funding for research.
Technological change is therefore not a smooth or uniform
process in time (Ayres, 1994). Barriers and subsequent
breakthroughs punctuate it.
The extent to which the technological opportunities
described here are taken up is closely related to the
competencies of different actors within the technological
field, and these competencies are a source of heterogeneity
among these actors (Cantner and Pyka, 1998). On the one
hand, opportunities can be utilized by established firms
with relatively established technology portfolios. This
would possibly require diversification of these technology
portfolios. However, the likelihood of diversification,
especially into unrelated technological fields, is reduced
by the bounded rationality of these established actors
(Simon, 1957). Moreover, inertia caused by specialization
contributes to the relative stability of the technology
portfolios of established firms (McKelvey, 1996; Breschi
et al., 2003), also more specifically where firms active in
biotechnology are concerned (McKelvey, 1996). On the
other hand, especially in high-technology sectors such as
biotechnology, newly founded firms have been perceived as
the main drivers of technological change and they thus
could be perceived as the type of actor most likely to utilize
these opportunities for innovation. In practice, established
firms have been seen to engage in partnering with these new
technology-based firms, this partnering functioning as a
mechanism to explore new technological opportunities
(Pyka and Saviotti, 2001).
From now on, we make an explicit distinction between
the level of a population of firms and the level of an
individual firm. We examine technology dynamics at these
two intertwined levels of analysis.2.1. Technological diversity of the population of newly
founded firms
Adhering to a population-level perspective, we aim to
provide insight into general developments of technological
fields in Dutch biotechnology. This enables us to examine
the development of technological fields over time. Popula-
tion-level technology dynamics is conceptualized as techno-
logical diversity of the population, indicating that in a sector
the number of technological fields can change over time, as
can the extent to which firms are working in these fields. To
qualify the notion of technological diversity, we use the
nature of changes in technological diversity. Over time, the
technological diversity of a population can either decrease,
increase or remain stable. This nature of development in
diversity is conceptualized by the notions of convergence1
and divergence. We speak of technological convergence
when technological diversity decreases over time, and of
technological divergence when the technological diversity
increases over time.
In order to evaluate developments in the technological
diversity of the subsequent populations of newly founded
firms, we operationalize this concept using two indicators.
On the one hand, we incorporate a factor addressing the
quantitative aspect of this diversity, namely a measure of
the number of different technological fields that is covered
by the population of newly founded firms. On the other
hand, we also incorporate a more qualitative aspect of
diversity, namely related to the variation in the relative
contribution of each of the technological fields. This
implies using both the number of different technological
fields represented over time as well as a measure for the
variation in the prominence of these different technological
fields. In this study, we use the standard deviation (SD) of
the annual shares of the different fields as a measure of
their relative prominence: a standardized way of measuring
the deviation from the mean annual share (Wonnacott and
Wonnacott, 1990).
Combined, developments in the number of fields and the
SDs of the shares of these fields over time give us some
insight into the question whether there is some extent of
technological convergence, divergence or stability in the
population of newly founded firms over time. Our
interpretation of the results according to convergence/
divergence/stability is given in Table 1. Possibly counter-
intuitively, decreases in the SD of annual shares of
technological fields indicate technological divergence, as
different fields are more equally addressed and technolo-
gical kernels dissolve. Increases in the SD of annual shares
of technological fields addressed are a signal of technolo-
gical convergence of the population of firms, as the
prominence of certain fields compared to others increases,
indicating the emergence of technological kernels. On the
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fields addressed is a signal of technological divergence
of the population. When combining developments in
the number of fields addressed and in the SD of the
annual shares, nine different combinations can be of
relevance, as shown in Table 1. When developments in
the SD of the shares and number of fields have opposing
effects on patterns of technology dynamics of the popula-
tion, we are not able to weigh these effects and determine
an overall effect; hence the term ‘indeterminate’ in Table 1.
The trend in the relative share of each subfield at tn as
compared to tn1 indicates whether technological kernels
emerge with a relatively larger share as compared to other
subfields.
These patterns of convergence, divergence or stability
are expressed at the level of the population and thus at the
level of a technological field in general. In this study, these
patterns are composed of patterns initiated at the micro-
level, namely by newly founded firms. This implies that
shifts in the annual shares of technological fields are
initiated at the micro-level by differences in technological
positioning of newly founded firms over time. These
technological opportunities as perceived by these newly
founded firms drive subsequent technological develop-
ments within the sector. Therefore, we link these develop-
ments in technological fields to technology development
within firms, by providing an overview of the different
technologies that firms combine. These technology portfo-
lios of firms represent the building blocks that constitute
patterns of technology dynamics at the level of the
population.Table 1
Operationalization of patterns of technology dynamics at the level of the
population.
SD(shares) No. of fields
m Stable k
m Indeterminate Convergence Convergence
Stable Divergence Stability Convergence
k Divergence Divergence Indeterminate




TF4      
TF5
TF6
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TF10      
Fig. 1. Opportunity matrix of2.2. Technology dynamics visualized as movement of
subsequent populations of newly founded firms across an
opportunity matrix
The first step in visualizing technology dynamics, at both
the level of the firm and the technology, is to construct a
so-called opportunity matrix, as given in Fig. 1. The rows
and columns of this matrix define the technological
subfields within a technology. Technology dynamics
visualized in this way is a function of the availability and
distribution of knowledge within the population of firms.
Each founding of a firm can be filled out in this matrix.
A founding of a firm on the diagonal implies that an
entrepreneur starts business activities as a specialist. A firm
can also combine two or more technological fields at
founding and thus be founded based on heterogeneous
knowledge. As Levinthal (1998) argues, a major source of
opportunities for innovation is ‘speciation’, i.e. the migra-
tion and application of an existing technology to other and
new application domains. Although the initial technologi-
cal shift from one domain to another may be small, the
speciation event may trigger a substantially new and
divergent trajectory. Moreover, innovation is not necessa-
rily equated with change of a single technology. Rosenberg
(1982) addressed the role of complementarities: a particular
technology can move forward because of inventions and
improvements of other technologies. This is also the case
for biotechnology. ‘Older’ DNA/protein-based technolo-
gies are now complemented by genomics-based ‘newer’
technologies such as bioinformatics and proteomics.
Then, a question that arises is how a population of newly
founded firms fills the matrix, and whether they fill mainly
diagonal cells of the matrix, or do they also fill off-diagonal
cells, and which of the possible combinations of technolo-
gical fields are prominent. We are also interested in whether
these prominent combinations remain prominent over
time.
After founding, firms can diversify their technology
portfolio, in a related or unrelated manner, which would
imply movement of this firm across cells of the opportunity
matrix. In this study, we do not empirically address
diversification strategies of individual firms over time, as
we study newly founded firms.TF6 TF7 TF8 TF9 TF10 
     
     
     
     
     
technology development.
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instrument for studying technological change, it also has
certain limitations. It enables visualization at, at most, a
two-dimensional level. This implies that a firm can be
attributed only to two technological fields. In order to
overcome this limitation we use network visualization
software NetDraw (Borgatti, 2002) to depict the two-
dimensional opportunity matrix, and generate figures in
which the nodes are different technological fields that have
been discerned, and linkages between these nodes represent
firms that combine knowledge of different fields. A similar
methodology was also used by Saviotti et al. (2005), for
examining knowledge bases of firms using patents of these
firms and their corresponding patent categories.
In the next section, we will start with a description of the
development of modern biotechnology and a classification
of technological fields within this sector, which could fill
the first row and first column of the sketched opportunity
matrix. Subsequently, further clarification of the research
methodology employed, including the method of collecting
the firm-level data on the inclusion of technological fields
in their technology portfolios, will be provided.
3. Development of modern biotechnology, data collection
and measurements
Various generations of technological change could be
distinguished following the rise of the biotechnology
industry over time (see also Hopkins et al., 2007). Prior
to the 1880s, plant extracts had been the most important
product source. From 1880 until 1930, physiological
chemistry and the extraction of natural products came
up, and synthetic organic chemistry became more impor-
tant. During the 1930–1960s organic chemistry and soil
microbiology became the most important scientific fields,
with the 1950s being the golden age of synthetic drug
discovery (Santos, 2003). From 1953 onwards, based on
the discovery of the structure of DNA by Watson and
Crick, an era of new biotechnology products and processes
began. The developments of recombinant DNA technology
and recombinant DNA versions of natural products were
very important in the 1970s and 1980s, respectively. In
2003 the complete sequence of the human genome had been
mapped in the HUGO project, making extensive use of
bioinformatics to ease the sequencing procedures. Firms at
the forefront of biotechnology research are now concen-
trating more on the so-called small molecules, designed by
bioinformatics, combinatorial chemistry, rational drug
design and high-throughput analysis techniques (Gass-
mann et al., 2004).
Furthermore, Walsh (2005) states that while the focus is
now on protein-based biopharmaceutical products, mostly
being engineered products, in the future, alternative
production and delivery systems will come up, such as
transgenic-plant-produced products and non-parenteral
delivery routes. In addition, more attention will be given
to nucleic-acid-based therapeutics, such as gene therapy,antisense technology, RNA interference technology, geno-
mics-based technologies and stem-cell-based therapies.
3.1. Towards a refined classification of technological fields in
modern biotechnology
Modern biotechnology is a wide emerging technological
area and comprises a broad range of scientific and
technological fields. Especially from 1970s onwards, many
different fields have been involved, and new technological
fields, such as bioinformatics, proteomics and pharmaco-
genomics have been coming up. In order to analyse the
patterns of technology dynamics within modern biotech-
nology developments, this paper will first develop a refined
classification of the discernable technological fields. In
order to unravel the precise scientific and technological
(sub)specializations within broad technological fields, we
are not using the broad IPC-codes involving biotechnology
often used in patent studies, such as C07H (sugars,
derivatives of nucleotides, nucleotides, nucleic acids) or
C12S (processes using enzymes or micro-organisms to
liberate, separate or purify pre-existing compounds).
We started with the official OECD classification of
biotechnology fields (OECD, 2001), identifying five broad
categories (McKelvey et al., 2004): (1) DNA (the coding);
(2) proteins and molecules (the functional blocks); (3) cell
and tissue culture and engineering; (4) process biotechnol-
ogy and (5) sub-cellular organisms.
Taking into account all the new developments occurring
in the various branches of modern biotechnology, we
considered this OECD classification into five technological
fields too small to cover all the various biotechnology
developments. Based on the work of Campbell et al. (1999),
Crommelin and Sindelar (2002), Oosterwijk (2003) and
Walsh (2005) on future directions of biopharmaceuticals,
we added various scientific and technological fields and
subfields to the five OECD categories in order to
complement them with more recent insights (see Table 2).
As can be observed in Table 2, some of the distinguished
technological fields have been divided into subcategories to
cover all the important technologies related to the main
technological field. For example, the technological field of
‘proteins and other molecules’ covers five subcategories:
synthesis and sequencing of proteins and peptides, isolation
and purification of proteins, protein engineering, proteo-
mics, and naturally derived products.
Starting from the classification in 11 main technological
fields of biotechnology and the involved subcategories (see
Table 2), an innumerable amount of combinations are
possible. From a market development perspective, it is
interesting to explore which Dutch firms are so-called
‘boundary spanners’ in the biotechnology business, cross-
ing the borders of their own knowledge and technological
field and looking for opportunities to combine the knowl-
edge of different technological fields. Which technological
fields are then expected to be combined in practice? We will
give some illustrative examples:
ARTICLE IN PRESS
Table 2
Classification of technological fields and subfields in modern biotechnol-
ogy.
1. DNA/RNA: all the topics on DNA coding, and transcription of DNA
into RNA. Subfields:
a. Gene probes, genetic engineering
b. DNA-RNA sequencing/synthesis/amplification/purification
c. Functional and comparative genomics, structural genomics
d. Transgenic animals
e. DNA microarrays and oligonucleotide microarrays
f. Single nucleotide polymorphisms (SNPs)
g. Pharmacogenetics and pharmacogenomics: related to response to
drug treatment
h. Oligonucleotides: short segments of DNA
I. Antisense technology/triplex technology
II. Aptamer technology
2. Proteins and other molecules: all the topics on functional peptide and
protein blocks. Subfields:
a. Sequencing/synthesis of proteins and peptides







e. Naturally derived products
3. Cell and tissue culture and engineering: all the topics on cell and tissue
cultures. Subfields:





4. Process biotechnology: all the topics on bioreactors, fermentation,
bioprocessing, bioleaching, biopulping, biobleaching,
biodesulphurization, bioremediation and biofiltration.





6. Bioinformatics and development of tools: including the following
subfields:
a. Construction of databases on genomes
b. Modelling complex biological processes, including systems biology





V. 3-D structures engineered proteins (crystallography, NMR,
spectroscopy, protein modelling)
7. Nanobiotechnology: applies the tools and processes of nano/
microfabrication to build devices for studying biosystems and
applications in drug delivery, diagnostics etc.
8. Glycobiology: synthesis of glycolipids and glycoproteins
(carbohydrates and branched oligosaccharides, covalently bonded to
lipids and proteins, respectively), important in cell–cell recognition.
9. (Bio)materials: includes material intended to interface with biological
Table 2 (continued )
systems to evaluate, treat, augment or replace any tissue, organ or
function of the body. These can be used to make implants, protheses
and surgical instruments.
10. Bioassays: test to determine the strength or biological activity of a
substance, such as a drug or hormone, by comparing its effects with
those of a standard preparation on a culture of living cells or a test
organism.
11. Drug targeting: a strategy aiming at the delivery of a compound to a
particular tissue of the body.
T. van der Valk et al. / Technovation 29 (2009) 247–264 253From a market perspective, it could be argued that the
broad technological fields of DNA/RNA handling (cate-
gory 1) and protein synthesis/sequencing (category 2) are
quite different, which could possibly come together by
means of new genomics-based technologies such as
pharmacogenomics, proteomics and metabolomics.
Synthesis of specific DNA/RNA fragments (category 1)
or of specific peptides or other molecules (category 2) is in
practice often combined with identification techniques of
those fragments or molecules (category 6). This identifica-
tion then gives possibilities to apply these molecules as
antibodies or as vaccines (category 3). In this way,
categories 1–3 are also often combined.
Firms exploiting process biotechnology (category 4) often
have to deal with enzymes and fermentation processes.
These enzymes are proteins or DNA/RNA molecules with a
specific catalytic function. The synthesis/sequencing and
engineering of these enzymes (proteins/DNA/RNA) fall in
category 2 and category 1, respectively. In addition,
antibody engineering, fusion proteins (category 2), and cell
and tissue engineering, especially vaccine/immune stimulants
(category 3) and also viral RNA inhibition (category 1) via
immune suppression (category 3), are often combined. .
Bioinformatics could in practice be regarded as a broad
enabling technology for more technological (sub)fields
(category 6). It is based on knowledge of genomics and
proteomics (categories 1 and 2), applying modern IT
technologies, building electronic databases of genomes and
protein sequences, and computer modelling of biomole-
cules and biologic systems. Furthermore, bioinformatics
firms (category 6) sometimes deliver structural data for
potential drug targets to firms developing drug delivery
systems (category 11).
To sum up, in order to analyse technology dynamics
patterns within modern biotechnology we needed a refined
classification of involved technological fields and subfields.
A biotechnology classification of 11 main categories and
related subcategories of technological fields has been
provided. In the following section, the method of data
collection will be explained.
3.2. Research population and data gathering
The population of firms studied here comprises all of the
DDLSFs that were established in the period 2000–2004.
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needed to be registered at the Dutch Chamber of
Commerce and have life sciences as their core business.
The definition of life sciences used here is derived from the
BioPartner Network (BioPartner, 2005, p. 188) and refers
to ‘‘those firms that apply the possibilities of organisms,
cell cultures, parts of cells or parts of organisms, in an
innovative way for the purpose of industrial production.
They may also supply related services, and hardware and
software.’’ This definition is somewhat broader than just
firms focussing solely on modern biotechnology. In total,
93 firms were included in the study.
In order to provide an overview of technologies focussed
on by DDLSFs, these firms were characterized according
to their in-house technologies. The data used for this were
primarily obtained from the websites of the firm. In a few
cases, if no information was available online, the informa-
tion included in their firm profile in the different
BioPartner reports was used (BioPartner, 2003, 2004,
2005). This approach differs from the frequently applied
method of patent counting and analysis, as was explained
in the introduction.
To be able to take into account the temporal aspect of
patterns of technology dynamics, we use the year of
founding of the firms. The rationale for using this method
of collecting data on technological focus at founding is
related to the specific characteristics of the population of
firms we study. It has already been shown that in modern
biotechnology, technological changes are primarily in-
itiated by the entry of new firms, as opposed to shifts in
the technological focus of already existing firms (Lemarié
et al., 2000; Pyka and Saviotti, 2001). Moreover, the firms
studied here are very young and small firms, each having its
own highly specific knowledge on which its existence is
based. These factors make it unlikely that their technolo-
gical focus has already clearly switched to an entirely new
focus since founding. We do acknowledge the possibility of
shifts in the technological focus of these firms, resulting in a
more diversified technology portfolio. However, if such a
shift has occurred, it is still expected that the core of this
focus has remained similar. It is also more likely that they
engage in related diversification, as opposed to unrelated
diversification (Deephouse, 1999).
Beforehand, different technological fields were identified
based on relevant literature, as has already been explained.
The in-house technology portfolios of the firms were
compiled at the end of 2005. The internet sites of the firms
were studied separately by two researchers, who subse-
quently attributed the firms to their relevant technological
field(s). To validate the results obtained, the two databases
compiled in this way were compared and differences were
identified, discussed, looked up again and decided upon.
Working with the list of technological fields was an
iterative process; as the different firms were examined for
their technological focus, some categories were combined
while others were added. This is considered to be relevant
as the objective of this part of the study was to give anoverview of technological developments in the Dutch life
sciences.
3.3. Measurements
As was indicated in Section 2, to measure technological
diversity we take into account the number of fields covered
by these firms, and the SD of the annual shares of these
fields. The SD is used as it represents a standardized way of
measuring the deviation from the mean annual share
(Wonnacott and Wonnacott, 1990). The first step in
determining this SD is to calculate the annual shares of
each field, which are the number of firms founded on each
specific field in a year divided by the total number of firms
founded in a year. Subsequently, the SD of these shares is
calculated.
In order to address the extent to which firms combine
technological (sub)fields, we have also compiled a distribu-
tion based on the shares of firms focussing on a specific
number of technological (sub)fields. These shares have
been calculated by dividing the number of newly founded
firms in a certain period that combine a specific number of
technological (sub)fields by the total number of firms
founded in that period. We make use of the skewness and
kurtosis of the frequency distribution of the firms across
the number of fields combined to assess whether this
distribution deviates from that of a normally distributed
random variable.
To be able to take into account explicitly the way in
which technology dynamics at the level of the population
are shaped by differences in the technology portfolios of
newly founded firms over time, we have used network
visualization programme NetDraw (Borgatti, 2002). Firms
that were on the diagonal of the opportunity matrix in each
year in each field were counted and the annual totals per
field were imported into the figures as attributes of the
fields, determining their relative size compared to the other
fields in a particular year. This methodology is similar to
the one used by Saviotti et al. (2005) for visualizing the
knowledge bases of firms using patents and their corre-
sponding patent categories. In addition to the method of
visualization that was used by Saviotti et al. (2005), we are
able to show individual firms within these figures.
Furthermore, we show firms working on one main field
by adding their numbers as attributes of technological
fields.
In the following section, the results will be discussed. We
will start with the results concerning patterns of technology
dynamics on the level of the population of firms, and
subsequently focus on the role of individual firms in the
developments of these patterns, using network visualiza-
tion.
4. Results
Table 3 provides an overview of the prominence of the
different biotechnology-related technological fields in the
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Table 3
Prominence of different biotechnology-related fields in the Netherlands.
Technological field No. of firms active in
the field
1. DNA/RNA: 17, of which:




(c) Functional and comparative genomics,
structural genomics
4
(d) Transgenic animals 0
(e) DNA microarrays and oligonucleotide
microarrays
6
(f) Single nucleotide polymorphisms (SNPs) 1
(g) Pharmacogenetics and pharmacogenomics:
related to response to drug treatment
1
(h) Oligonucleotides: short segments of DNA 2, of which:
I. Antisense technology/triplex technology 2
II. Aptamer technology 0
(i) Ribozymes 0
2. Proteins and other molecules 39, of which:
(a) Sequencing/synthesis of proteins and peptides 10
(b) Protein isolation and purification 5
(c) Protein engineering 18, of which:
I. Site-directed mutagenesis 2
II. Enzyme engineering 4
III. Fusion proteins 3
IV. Antibody engineering 8
(d) Proteomics 4
(e) Natural products 8
3. Cell and tissue culture and engineering 11, of which:
(a) Cell/tissue culture, cell line development 2
(b) Tissue engineering 1
(c) Cellular fusion 0
(d) Vaccine/immune stimulants 8
(e) Embryo manipulation 0
4. Process biotechnology techniques 4
5. Gene and RNA vectors 2, of which:
(a) Gene therapy 0
(b) Viral vectors 0
(c) DNA transfer 2
6. Bioinformatics/development of tools 23, of which:
(a) Construction of databases on genomes 0
(b) Modelling complex biological processes,
including systems biology
0
(c) Instruments, devices applied to biotech 22, of which:
I. Bioinformatics 2
II. High-throughput screening 6
III. Combinatorial chemistry 2
IV. Chiral chemistry 2
V. 3-D structures engineered proteins 4
7. Nanobiotechnology 1
8. Glycobiology 0
Table 3 (continued )




11. Drug targeting 9
Total number of firms 82 out of 93
T. van der Valk et al. / Technovation 29 (2009) 247–264 255Netherlands. This table provides results on 82 out of the 93
firms that were originally studied here. This is due to the
fact that the technology portfolios of the 11 remaining
firms could not be evaluated, because of, for instance, a
lack of information in general, or a lack of data on the
specific technologies used by these firms. Also, the
population of life sciences firms included some clinical
research organizations, which will not be taken into
account here as these organizations are purely service
oriented. It is important to note that a single firm could be
attributed to more than one technological fields.
Table 3 shows that the most prominent technological
field is proteins and other molecules, within which protein
engineering is an important area. Sequencing and synthesis
of RNA/DNA as well as proteins and other molecules are
also core fields. Twenty-two firms are in some way involved
in R&D in the field of instruments and devices, and 12 in
bioassays. No firms seemed to be working specifically on
glycobiology. Thus, this field is apparently not focussed on
by DDLSFs (yet). In the following sections, technological
diversity of the population of newly founded firms will be
examined further.
4.1. Developments in the technological diversity of the
population of newly founded firms
The following figures each provide information on the
extent to which different technological fields are covered by
the population of life sciences firms in 2004, according to
their year of founding. As the primary aim here is to
illustrate the methodology applied, we limit ourselves to
presenting only the results on all main categories (exclud-
ing glycobiology as there are no firms working on this field)
and the DNA/RNA subfields. In each figure an additional
line is included that represents the total number of life
sciences firms founded in that year. The scale of this line is
presented as a secondary y-axis, on the right side of the
figure. The figures make it possible to evaluate whether the
technological diversity of the population of newly founded
firms has increased, decreased or remained stable over
time. As can be observed from Fig. 2, the number of firms
founded each year and included in this study first decreases
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Fig. 3. Technological diversity of newly founded DDLSFs: all main fields
(1–11).
T. van der Valk et al. / Technovation 29 (2009) 247–264256figure shows that until 2004, the ‘protein’ field was
relatively prominent compared to the other technological
fields that were covered by newly founded firms. Also, in
2002 relatively many firms were founded working on
bioinformatics and tools. In 2004, several fields have a
similar share, and there does not appear to be a clear
technological focus of newly founded firms in the Dutch
life sciences.2
Fig. 3 provides information on the development of
technological diversity of the population of newly founded
firms as measured by the number of technological fields
and the SD of the annual shares of these technological
fields over time. In order to gain an overall insight into the
development of these two parameters, linear regression
lines have been added to the figure. Studying this figure in
detail, it can be concluded that from 2000 to 2001 there is
technological convergence, as during this period the
number of technological fields addressed decreased while
the SD of the shares of these fields increased. For the
following year, 2001–2002, the number of fields addressed
remained stable, while the SD of the shares decreased
slightly. Combined, these developments indicate slight
technological convergence. For 2002–2003, we are not able
to determine whether the extent of diversity of the
population increased or decreased, as developments in
the SD of the annual shares and the number of fields
covered have opposing effects on this extent. From 2003
onwards, the number of technological fields increased,
while the SD of the annual shares decreased, suggesting
technological divergence.
The figure shows that developments in the number of
fields covered as well as the SD of the shares of these fields
were volatile from 2000 to 2004. Overall, with the increase
of the number of firms founded each subsequent year, the
number of different technological fields on which R&D2Note that the shares of the different technological fields do not add up
to one in each year; after addition they exceed one as a firm could be
attributed to multiple technological fields.activities are conducted also increased, but only slightly.
Also, over time, the SD of the shares of these technological
fields within the population of firms decreased slightly.
These findings indicate that more different technological
fields became covered by the population, and the different
new firms founded became more equally distributed over
these fields over time. This result thus signals that the
variation in the focus of R&D efforts in the Dutch life
sciences did not decrease over time; it rather increased
slightly.3
Figs. 4 and 5 provide an overview of the development of
different DNA/RNA-related fields over time, with which it
can be derived that the number of technological subfields
covered within the main DNA/RNA category fluctuates
over time. This development in the number of subfields3As the number of values for the number of fields and the SD of the
shares of these fields are limited to five, due to our focus on developments
from 2000 to 2004, we have not been able to determine the statistical
























Total no of firms
1999
year
2000 2001 2002 2003 2004 2005












No of f ields
SD of shares
Lineair (SD of shares)












2000 2001 2002 2003 20052004
Fig. 5. Technological diversity of newly founded DDLSFs: DNA/RNA
fields.
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total number of firms founded each year Sequencing/
synthesis of DNA/RNA was relatively prominent in the
first years, but this prominence decreased in the last few
years studied. Developments in the shares of the different
subfields have been rather similar since 2000, which is also
reflected in the low SDs of the shares of these subfields.
Looking more closely, it can be concluded that from 2000
to 2001, developments in the technological diversity were
indeterminate. From 2001 to 2002 the technological
diversity of the population increased, as the number of
fields addressed increased while the SD of their annual
shares was stable. From 2002 to 2003, developments were
again indeterminate. From 2003 to 2004 the number of
fields addressed decreased while the SD of their annual
shares increased, signalling technological convergence.
Overall, the technological diversity of newly founded firms
in the field of DNA/RNA has been relatively stable,
implying that patterns of technology dynamics neither
clearly converged nor diverged.
Figs. 2–5 have provided information on developments in
the prominence of different technological fields over time,
as the population of founded firms changes. Moreover,these figures have provided insight into the extent to which
patterns of technology dynamics can be characterized as
convergent, divergent or indeterminate. Overall, the results
obtained on the main fields (Fig. 3) reflect a slightly
growing diversity within the populations of newly founded
firms over time, rather than a decrease of this diversity, as
there is an increase in the overall number of technological
fields covered, while the SD of the annual shares of these
fields declines slightly. Developments of the different
technological subfields of the main field of DNA/RNA
were relatively stable over time.
These patterns of technology dynamics are initiated at
the level of the firm by new foundings in the different
technological fields. This will be addressed in the following
section.
4.2. Technology dynamics at the level of the firm
In this section, we will present our results on technology
dynamics at the level of the firm. In Table 4 the frequency
distribution of the number of technological subfields
covered per firm is presented. As can be observed from
this table, many firms combine two or more technological
subfields in conducting their R&D. In order to assess the
derivation of this distribution from a normally distributed
random variable we use its skewness and kurtosis. Overall,
these measures indicate a significant deviation from a
normal distribution, in which a relatively large number of
firms focuses on one or two technological subfields only
(skewness ¼ 1.580; SDskewness ¼ 0.266). These findings on
the skewness and kurtosis of these distributions indicate
that DDLSFs tend to be significantly technologically
specialized.
Overall, 38 firms were attributed to one technological
subfield only. Fig. 6 provides an overview of the
biotechnology-related technological fields these 38 Dutch
firms are working in. ‘Bioinformatics’ and ‘proteins and
other molecules’ are the technological fields these firms
typically focus on. Within these two main categories,




4 firms = 11%
3. Cell & tissue 
culture 
2 firms = 5%
2. Proteins & other 
molecules
9 firms = 23%
1. DNA/RNA
2 firms = 5%
11. Drug targeting
1 firm = 3%
10. Bioassays
4 firms = 11%
9. Biomaterials
4 firms = 11%
6. Bioinformatics
12 firms = 31%
Fig. 6. Distribution of technological fields, for DDLSFs working on one
biotech-related subfield (N ¼ 38).
Table 4
Frequency distribution of the number of technological subfields per firm.








4Using the explanation given earlier in this section, these eight firms can
be identified by counting the number of continuous black lines, each
representing a firm combining knowledge of two main fields, and adding
to this number the firms represented by differently styled lines. In this case
this calculation leads to 6+2 ¼ 8.
T. van der Valk et al. / Technovation 29 (2009) 247–264258dominant as all 12 bioinformatics firms specialize in this
subfield.
4.3. The network visualization figures
In a further attempt to provide an answer to the third
research question, this section addresses the extent to
which knowledge related to different technological fields
specified is combined by newly founded DDLSFs.
As Table 3 shows, a large share of firms combine two or
more technological subfields in conducting their R&D. In
order to gain insight into which fields are combined and
how these combinations of fields develop over time, we
have compiled figures using the network visualization
programme NetDraw (Borgatti, 2002). To enhance the
clarity of these figures, the results on different subfields
have been aggregated to the corresponding main field.
Therefore, in these figures, the nodes in the networks
represent the main technological fields that were empiri-
cally identified in biotechnology (see Table 2). As our main
aim is to illustrate the usefulness of network visualization
in unravelling technology dynamics, only the figures of
2000, 2002 and 2004 have been included here. The data that
were used to compile these two figures are given in
Appendix A. Data on the other annual populations (2001
and 2003) are also included in this appendix.
The total number of firms founded in each year (N) is
given directly below the figures. The relative size of each
node in each figure was determined by the relative number
of firms working only in that main technological field in a
particular year. The numbers depicted inside the nodes
represent the actual number of firms working only in this
main field. This implies that firms attributed to a single
node are either specialists or firms combining subfields of
that main field. Field 8 (glycobiology) has been omitted
from the figures as no firms are working in this field.
The smallest nodes in each figure indicate zero foundings
in that corresponding field only in that year. Firms
combining knowledge of different technological fields are
represented by lines connecting the nodes. A continuous
(black) line represents a firm that combines knowledge of
the two main technological fields the line connects. Dashed,
dotted or other non-continuous lines represent firms
combining knowledge of more than two main technologicalfields. Again, the specific fields that are combined by a
single firm are those connected by lines that are similarly
styled. Being based on this, these figures provide informa-
tion on the development of the technological fields specified
and how these developments are induced by foundings of
firms over time, thus from a micro-level perspective. They
show how firms, by conducting their R&D, link different
technological fields. For each figure, some examples will be
given of the specific technological focus of firms combining
knowledge of different fields.
As shown in Fig. 7, in 2000, 13 firms were founded,
which work in one main field only (as the number depicted
in the nodes adds up to 13). Most of these firms work in
field 2 (‘proteins and other molecules’) or 6 (‘instruments’).
In total, eight firms combine knowledge of more than one
main field.4 When examining firms combining knowledge
of two or more technological fields, the prominence of field
2 is striking: five out of the eight firms that combine
knowledge of different fields employ knowledge belonging
to this technological field. Many combinations of different
fields are made in 2000. For instance, one firm is engaged in
the development of natural molecules, which includes
assessing their biological activity using bioassays (combin-
ing fields 2 and 10). Another firm provides adjuvants
(belonging to field 2) for vaccines (field 3).
In 2002, the number of foundings is 13, and these firms
are almost equally divided between firms working on one
main field and firms that combine different fields (seven
working on one main field, six firms that combine main
fields). As can be derived from Fig. 8, technological field 2
remains prominent when the fields that firms combine are
concerned. However, the number of firms working on this
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Fig. 7. Technological fields (TFs) addressed by newly founded DDLSFs
in 2000 (N2000 ¼ 21; thirteen working in one main field, eight combining
main fields).
Fig. 8. Technological fields addressed by newly founded DDLSFs in 2002
(N2002 ¼ 13; seven working on one main field, six combining main fields).
Fig. 9. Technological fields addressed by newly founded DDLSFs in 2004
(N2004 ¼ 18; twelve working in one main field, six combining main fields).
T. van der Valk et al. / Technovation 29 (2009) 247–264 259main field only is low. In this year, field 6 attracts the most
specialists and firms combining subfields belonging to the
same main field. To illustrate, the firm combining fields 1
and 3 focuses on the inhibition of viral RNA. Both firms
combining fields 2 and 11 are focussed on the development
of molecules with specific properties (field 2), directed at
specific targets (field 11), or in specific formulations (field
11). One of these firms combines this knowledge with
knowledge on chiral chemistry (belonging to field 6).
As shown in Fig. 9, in 2004, 12 firms focussed on one
main field, while six combined knowledge of two fields or
more. Two of these firms that combine main fields focussed
on fields 9 (‘biomaterials’) and 11 (‘drug targeting’). These
firms are active in the development of drug delivery systems
(field 11) using (biodegradable) implants (field 9). Further-
more, 2004 is the first year in which a new firm was
established that incorporates nanobiotechnology in itstechnology portfolio. It is also the first year in which a
direct connection was made by a firm between fields 1 and
5. This firm focuses on the development of gene (field 1)
and protein (field 2) therapeutics, for which it uses DNA
transfer (field 5).4.4. Overall patterns of technology dynamics: relating the
firm level to the population level
Overall, Figs. 7–9, combined with additional data on the
years 2001, 2002 and 2003 given in Appendix A, show that,
from the total number of 82 firms, 50 firms are either
specialists or combine knowledge of subfields belonging to
the same main field, as 50 firms are working on one main
field only. The 32 firms that remain are firms that combine
knowledge belonging to at least two different main fields
that were discerned. Frequently occurring combinations of
main fields include fields 2 (proteins and other molecules)
and 6 (instruments and tools), 2 and 11 (drug targeting)
and 1 (DNA/RNA) and 2. Some other main fields, such as
field 4 (process biotechnology), remain rather isolated,
which is in accordance with results that were presented
earlier, in Fig. 6.
In order to relate the findings presented in this section to
the findings presented earlier on developments of the
technological diversity, we here address the extent to which
firms working in one main field and firms combining fields
contribute to the total number of fields covered by firms
annually. As is shown in Table 5, the number of different
fields covered by specialists is relatively stable over time: six
fields in 2004, four in 2002 and five in all other years. The
number of fields addressed by firms combining fields
founded in each year fluctuated from eight in 2000 to six
in 2001, 2002 and 2003, and eight in 2004. The total
number of different fields addressed each year, as was also
already depicted in Fig. 3, was determined by the extent to
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Table 5
Contribution of DDLSFs working in one main field and firms combining main fields to the total number of fields covered in each year from 2000 to 2004.
No. of fields covered by
DDLSFs working on one
main field
No. of fields covered by
DDLSFs combining
main fields
Overlap fields Total no. of fields covered
2000 (N ¼ 21) 5 (n ¼ 13) 8 (n ¼ 8) 4 9
2001 (N ¼ 15) 5 (n ¼ 10) 6 (n ¼ 5) 5 6
2002 (N ¼ 13) 4 (n ¼ 7) 6 (n ¼ 6) 4 6
2003 (N ¼ 15) 5 (n ¼ 8) 6 (n ¼ 7) 3 8
2004 (N ¼ 18) 6 (n ¼ 12) 8 (n ¼ 6) 5 9
T. van der Valk et al. / Technovation 29 (2009) 247–264260which firms are working in the same fields, information on
which is provided in the fourth column.
As can be derived from this table, in 2001 and 2002,
firms working in one main field are working in fields that
are also already covered by firms combining fields, as the
overlap in fields of these firms equals the number of fields
covered by firms working in one field. So, while the overall
number of different fields covered in each year to some
extent coincided with the number of firms founded in each
year, additional variation is generated by the extent to
which firms work on the same fields.
From Table 3 it was already derived that ‘proteins and
other molecules’ is the most prominent field in the Dutch
dedicated life sciences sector. From Figs. 8 and 9, it can be
furthermore derived that this overall prominence is a
resultant of the fact that this field is prominent where firms
working in one main field as well as firms combining fields
are concerned. Based on the figures presented in this
section, the decline noticed in the prominence of field 2 in
Fig. 2 in the years 2002 and 2004 can be attributed to a
decline in the number of firms working in this field only in
these years, relative to other years. In 2002 as well as in
2004, only one firm focussed solely on field 2.
Taking the network visualization figures into account, it
can be stated that the combinations of different fields made
by firms over time are volatile. However, there does seem
to be a dividing line between fields 6 and 11 on the one
hand, and 1, 5 and 10 on the other hand. Fields 2 and 3 are
combined with fields of either of these two groups, but
there are hardly any direct connections made by firms
between the different fields belonging to both groups. Our
results show that on the one hand, fields 6 and 11 are
combined with 2 and 3 to identify and develop (and in
some cases administer to patients) molecules with certain
characteristics, whereas fields 1, 5 and 10 are combined
with fields 2 and 3 in order to enable the development of all
sorts of analyses and diagnostics, including analysing the
genetic composition of organisms. Firms working on the
use of DNA or RNA for disease treatment purposes
represent an exception to this general tendency. An
example of such a firm is the firm combining fields 1 and
3 in 2002, which focuses on the use of RNA inhibition in
the development of therapeutics. The division of biotech-
nology fields into these groups of fields did not change overtime. There do seem to be new areas of application arising
over time. For instance, new opportunities arising from
developments in the fields of nanobiotechnology have led
to the founding of a firm in 2004 combining knowledge
from the nanobiotechnology field with the delivery of
therapeutics.
5. Discussion
Returning to the first part of the central question of this
paper, namely: ‘How can patterns of technology dynamics of
emerging technologies be conceptualized in general?’ it can
be concluded that the concept of technological diversity as
applied in this study provides useful insights into the
technological developments over time. On the level of the
individual newly founded firm, the ‘opportunity matrix’ of
technology development, combined with network visuali-
zation, gives insights into technology development. More
specifically, the second part of the research question was:
‘Which patterns of technology dynamics could be discerned
at Dutch dedicated life sciences firms?’ This question was
analysed by answering three more specific research ques-
tions. These are successively addressed below.
To answer the first more specific research question,
namely ‘Which technological fields can be discerned in
modern biotechnology, and how can these be classified?’ we
conducted a literature search for relevant technological
(sub)fields. This resulted in a list of 1 technological fields,
most of which were further specified into subfields. Overall,
Dutch policies aimed at stimulating founding of life
sciences firms have not triggered focus in the R&D efforts
of these newly founded firms. Rather, in an attempt to
answer the second research question, namely ‘Which
patterns in the development of the technological diversity
of the population of newly founded firms could be discerned
for subsequent annual populations of these newly founded
firms?’ we found that there has been an increase in the
number of technological fields covered by the newly
founded firms and research efforts of firms have become
more equally divided over these fields. These two tenden-
cies indicate increasing technological diversity of the
annual population of newly founded firms over time.
Apparently, forces increasing variation prevail over those
of imitation, which is in accordance with population
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man, 1980). Further research addressing technology
dynamics in the Dutch life sciences over a longer time
span would give insight into developments in technological
diversity in the long run. Finally, with regard to the third
research question specified, i.e. ‘To what extent are Dutch
dedicated life sciences firms newly founded in the period
2000–2004 specialists, focussing on one specific technological
(sub)field, and to what extent do they combine various
technological fields?’ it can be stated that a relatively high
share of firms (38/82) focus on one technological subfield
only and are specialists. This finding is in accordance with
the notion of Brittain and Freeman (1980), Orsenigo et al.
(2001) and Baum and Rao (2004) deriving from population
ecology that the emergence of new technological fields
induces the founding of specialists, exploring new techno-
logical opportunities embedded in specific technological
niches. ‘Bioinformatics’ was found to be a typical specialist
field, which is also the case in US biotechnology (Hall and
Bagchi-Sen, 2007). Furthermore, 12 firms combined two or
more subfields belonging to the same main technological
field. Next to these firms, some combinations of main fields
made by firms were frequently observed. This could be
explained by the fact that these fields are scientifically
closely linked together. In this respect, these technological
fields can be considered complementary rather than
competing, indicating the systemic nature of the technolo-
gical developments studied here (Barnett, 1990).
6. Conclusion and implications
The main contribution of this study is embedded in the
conceptualization of patterns of technology dynamics. On
the one hand, we have made use of the notions of
technological convergence and divergence on the level of
subsequent populations of newly founded firms. By
assessing both the number of fields covered by these
populations of firms over time, and the relative importance
of these fields, we have been able to provide insight into the
development of an emerging technology over time. On the
other hand, we have also introduced the so-called
opportunity matrix to gain insight into technology
dynamics at the level of the individual firm. Furthermore,
in order to visualize these dynamics we have made use of
network visualization. Further research could focus on the
elaboration of this tool and the coupling to traditional
variation, selection and retention models.
This paper aimed to provide insight into a conceptua-
lization of technology dynamics of emerging technologies.
Due to the low number of empirical studies on technology
dynamics in general, especially those not using patent data,
it is difficult to compare our results to other findings on this
topic. Although field 2 (proteins and other molecules) was
shown to be prominent, results on technological kernels are
volatile; there are fluctuations over time. The question that
arises then is to what extent some kind of convergence of
research efforts in biotechnology in the Netherlands wouldbe desirable to increase the chances of survival of these
firms. However, prior research on populations of biotech-
nology firms in France, Germany and the UK also noted
the absence of specialization of these firms on a national
level (Lemarié et al., 2000), which could indicate that this is
a general aspect of populations of biotechnology firms.
This is in accordance with the idea that biotechnology is a
global industry (Bartholomew, 1997). As indicated by
Ireland and Hine (2007), while firm success also depends on
organizational aspects, the quality and newness of the
research findings of the firms are eventually decisive. They
also substantiate the idea that the inability to bring about
change within their organization is an important reason for
failure of biotechnology firms (Ireland and Hine, 2007).
The precise specialization chosen by an individual firm
therefore is decisive for its survival on the long term. The
commercial viability of such highly specialized firms,
including the DDLSFs, is unclear. Over time they should
aim to commercialize their knowledge, as is already
apparent in US biotechnology, where a group of firms
has reduced its R&D intensity, and now focuses more on
the improvement of its business, for instance by interacting
with consumers and gaining access to distribution channels
(Hall and Bagchi-Sen, 2007). The increasing importance of
alignment with the market may reduce the variety within
young populations of biotechnology firms over time, as it
may lead to failure of certain organizations.
Taking part in networks of collaboration has been
indicated to be crucial for firm survival in biotechnology
(see for instance Xia and Roper, 2008). The prominent role
of research institutes in the network of DDLSFs is a clear
indication of the explorative nature of this network (Van
der Valk, 2007; Gilsing and Duysters, 2008). In exploita-
tion, these DDLSFs will need to collaborate with other
firms, as is already apparent from the central position of
some biotechnology firms in the US network (Powell et al.,
2005). The high degree of specialization of DDLSFs may
limit their opportunities to engage in joint development
(Kim and Higgins, 2007), and make them more fragile.
While the approach provided useful insights into
technology dynamics of an emerging technology, it also
has some limitations that need to be taken into considera-
tion when conducting further research. First of all, the data
used, namely information obtained from websites of the
firms studied, could result in biases in the results obtained.
More elaborate methods of data collection could be
introduced, for instance case study research based on
in-depth interviews. Secondly, due to the use of the year of
founding as the temporal dimension of technology
dynamics, we were not able to trace technological
diversification of individual firms over time. By making
use of other methods of data collection proposed above it
would be possible to gain insight into this diversification.
Next to this, the focus on the year of founding might also
provide biased results. There might be a discrepancy
between the technological focus at the year of founding
and the technological fields they are working in, in 2005.
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have been founded since 2000, we have been able to limit
this discrepancy, assuming that firms will stay in a
particular technological field for at least a couple of years.Appendix A. Data used to compile Figs. 8 and 9
























Fig. A1. The opportunity matrix of firms combining two main fields or less (N
firms founded in that year, in that specific field or a combination of two fields. F
in 2002, one firm was founded working on a combination of subfields of main
Table A1
Technological fields of firms combining three or more main fields (N ¼ 11).
Firm Field 1 Field 2 Field
Firm 1 2civ anti body 5c DNA transfer 10 bi
Firm 2. 2c prot engineering 3a cell line 6cv 3
Firm 3 1e arrays 2ciii fusion 10 bi
Firm 4 1b DNA seq synth 1c genomics 2d pr
Firm 5 2a prot seq/synth 2cii enzyme 6civ c
Firm 6 1a probes/engineering 2ci site directed 2ciii f
Firm 7 2d proteomics 3d vaccine 6cii h
Firm 8 1b DNA seq synth 2civ anti body 3d va
Firm 9 2civ anti body 3d vaccine 6cii h
Firm 10 1a probes/engineering 2c prot engineering 5c DN
Firm 11 2 proteins general 7 nanobiotech 11 drReferences
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